Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 310 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overweight Subjects Clear all
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

NCT00388180
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions
GW501516, GW590735
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band

NCT00543140
View directory record Official record
Conditions
Morbid Obesity
Interventions
REALIZE™ Swedish Adjustable Gastric Band
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years to 60 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Evaluation of Muscle Activation Efficiency in Challenging Subjects

NCT01811446
View directory record Official record
Conditions
Obesity, COPD
Interventions
Muscle Activation with Niveus and Intelect Devices
Device
Lead sponsor
Niveus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

NCT05064735
View directory record Official record
Conditions
Obesity
Interventions
semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
61
States / cities
Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 22, 2026, 2:37 PM EDT
Not listed Not applicable Interventional

Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35

NCT00999050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Gastric bypass for diabetic patients <35 BMI
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Jul 22, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3463251 in Healthy Participants

NCT03764774
View directory record Official record
Conditions
Healthy
Interventions
LY3463251, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

NCT02014740
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA Hypertension and Inflammation in Lean and Obese Subjects

NCT00721617
View directory record Official record
Conditions
Diabetes, Hypertension, Obesity
Interventions
Intralipid 20%, Normal Saline, Oral fat load
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

NCT00650806
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
35
States / cities
Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970
View directory record Official record
Conditions
Obesity
Interventions
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Ceftaroline in Normal and Obese Subjects

NCT01648127
View directory record Official record
Conditions
Drug Safety
Interventions
Ceftaroline
Drug
Lead sponsor
Keith A. Rodvold
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873
View directory record Official record
Conditions
Obesity
Interventions
ERX1000, Placebo
Drug
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2

NCT06068946
View directory record Official record
Conditions
Weight Loss
Interventions
VK2735, Placebo
Biological
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 22, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects

NCT02689661
View directory record Official record
Conditions
Metabolic Syndrome, Obesity, Neuropathy
Interventions
Not listed
Lead sponsor
Brian Callaghan
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT05134662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fort Myers, Florida • Sarasota, Florida • River Forest, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

NCT06445075
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Apitegromab, Placebo, Tirzepatide
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DELPHI in Subjects at Risk for Stroke and Dementia

NCT03884647
View directory record Official record
Conditions
Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions
DELPhI system
Device
Lead sponsor
QuantalX Neuroscience
Industry
Eligibility
50 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 22, 2026, 2:37 PM EDT
Recruiting Phase 2 Interventional

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

NCT07570758
View directory record Official record
Conditions
Obesity & Overweight
Interventions
ERX1000, Placebo
Drug · Other
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • Monroe, North Carolina • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects

NCT02151825
View directory record Official record
Conditions
Gut Microbiota, Adiposity
Interventions
Synbiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Texas State University, San Marcos
Other
Eligibility
18 Years to 64 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Marcos, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jul 22, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety

NCT00645216
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2009 · Synced Jul 22, 2026, 2:37 PM EDT